NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Wednesday that its revenues in the third quarter had slipped 5 percent year over year.

Total revenues for the three months ended Sept. 30 dropped to $7.9 million from $8.3 million a year ago, as growth in the company's Clinical Laboratories segment was offset by a decline in the Pharmacogenomics Services and Diagnostic Tools segments, the Omaha, Neb.-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.